A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma

Launched by THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIVERSITY · Apr 19, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at a specific type of blood test to see how well it can predict outcomes for patients with a rare form of cancer called Extranodal Natural Killer/T-cell Lymphoma (ENKTCL). Researchers want to find out if measuring the levels of a particular DNA marker in the bloodstream can help determine how likely patients are to survive or achieve remission after two years of treatment. The study will involve 72 patients who have just been diagnosed with this type of lymphoma and will compare two different methods of assessment to see which one is more effective.

To be eligible for this study, participants need to be newly diagnosed with ENKTCL, confirmed by a specific medical test. They also need to be able to provide written consent and attend follow-up appointments as needed. This trial is currently not recruiting participants, but once it starts, those involved can expect regular monitoring and support throughout the process. It's important to note that some individuals may be excluded if there are other health issues that could interfere with the study results.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • newly diagnosed ENKTCL confirmed by pathological tissue, the diagnostic criteria refer to the 2016 WHO diagnostic criteria
• • Sign written informed consent and be able to comply with the visits and related procedures specified in the protocol
• Exclusion Criteria:
• • The investigator believes that the subjects may have other factors that may affect the efficacy or safety evaluation of this study